Company Overview
About Loyal
Loyal is a veterinary biotechnology company founded in 2020 by Celine Halioua and headquartered in San Francisco, California. The company is developing pharmaceutical treatments designed to extend the healthspan and lifespan of dogs — large breeds in particular, which age faster and live shorter lives than small breeds. Loyal's approach is grounded in the biology of aging: targeting the hormonal, metabolic, and cellular mechanisms that drive age-related decline in dogs, with the goal of creating FDA-approved drugs that add healthy years to companion animals' lives.
Business Model & Competitive Advantage
Loyal's lead drug, LOY-001, achieved a landmark regulatory milestone in 2023 when it received an FDA reasonable expectation of effectiveness determination — the first longevity-focused drug for any species to receive this designation. This means the FDA determined that Loyal's mechanistic and preliminary data are sufficient to support a reasonable expectation that the drug will extend lifespan. Loyal is now conducting the additional studies required to complete the full approval pathway. A second candidate, LOY-003, is an oral daily drug for dogs of all sizes targeting similar aging pathways.
Competitive Landscape 2025–2026
The company has raised approximately $45M from investors including Greenoaks Capital, and has attracted significant attention as a proof-of-concept for applying longevity biology commercially — with implications beyond veterinary medicine for human aging research. Loyal operates at the intersection of veterinary pharma, longevity science, and companion animal wellness, a market where pet owners increasingly invest in preventive and life-extending care for their animals.
Key Differentiators
Emerging Innovator
Loyal is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Compare Loyal with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Loyal? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Loyal Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Loyal vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →